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Abstract
Background: Haemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder of immune regulation, and
HLH patients with mutations in genes including PRF1, UNC13D, STX11, STXBP2, SH2D1A, XIAP, and ITK were reported
to be primary HLH. Due to the different treatment options, the differentiation between primary and secondary HLH
is critical. Our previous studies have showed that a Th1/Th2 cytokine profile is diagnostic for HLH, yet the cytokine
profiles between primary and secondary HLH have not been compared. The aim of the study was to test whether
the Th1/Th2 cytokine profile could be used as a tool to differentiate between primary and secondary HLH.
Methods: A total of 45 hospitalized Chinese children with HLH during the period of February 2010 through
September 2012 were enrolled in the study. Fifty healthy children were enrolled as controls. Primary HLH related
genes were sequenced using genomic DNA samples. The Th1/Th2 cytokine levels including interferon-γ (IFN-γ),
tumor necrosis factor-alpha (TNF-α), interleukin (IL)-10, IL-6, IL-4 and IL-2 were quantitatively determined by
cytometric bead assay techniques.
Results: Primary HLH group (n = 4) included one patient with biallelic heterozygous mutations in PRF1 gene, and
three patients with hemizygous mutation in SH2D1A gene. Based on the available genetic data, the other 41
patients were classified into the secondary HLH group. When compared the cytokine levels between the two
groups, IL-4 level in primary-HLH was significantly lower than that in secondary HLH (P = 0.025), while IFN-γ level
in primary HLH had a tendency of statistically lower than that in secondary HLH (P = 0.051). Area under receiver
operating characteristic (ROC) curves of IL-4 and IFN-γ, IL-10, TNF-α, IL-2, and IL-6 levels were 0.841, 0.799, 0.506, 0.
494, 0.457, and 0.250, respectively. ROC curves showed that 1.7 pg/ml of IL-4 had sensitivity and specificity for
differentiation between primary and secondary HLH as 70.7 and 100.0 %, while 433.9 pg/ml of IFN-γ had
sensitivity and specificity as 51.2 and 100.0 %, respectively.
Conclusions: HLH patients with lower IL-4 and IFN-γ levels have higher possibility to be primary HLH. The
cytokine profile may be used as an additional tool for the quick differential diagnosis between primary and
secondary HLH.
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Background
Haemophagocytic lymphohistiocytosis (HLH) is a life-
threatening disorder of immune regulation, characte-
rized by a highly stimulated, but ineffective immune
response to antigens, which results in cytokine storm
and inflammatory reaction [1]. HLH is not a single
entity, but a clinical syndrome that can be encountered
in association with various underlying diseases leading
to similar characteristic clinical and laboratory presenta-
tions. Briefly, the diagnosis of HLH requires either a
genetic diagnosis, or fulfillment of 5 out of 8 clinical cri-
teria including fever, splenomegaly, bicytopenia, either
hypofibrinoginemia or hypertriglyceridemia, hyperferriti-
nemia, elevated soluble interleukin-2 receptor (sCD25 or
sIL2R), impaired natural killer (NK) cell cytolytic func-
tion, or the observation of hemophagocytosis in bone
marrow, spleen, or lymph nodes [2]. Based on the eti-
ology, HLH can be classified into two types, primary
HLH (with genetic mutations), and secondary HLH (no
known mutations). Epstein–Barr virus (EBV) infections
seem to be very common in HLH patients, especially in
Asian countries [3–7]. Beside EBV infection, cyto-
megalovirus (CMV) infection is another common cause
in HLH patients [8, 9]. Clinically, prompt and accu-
rate diagnosis is critical to initiate definitive therapy.
Unfortunately, the clinical features are identical in
primary and secondary HLH, and both forms are
often triggered by infections, so it is difficult to distin-
guish between these two types [8]. Furthermore, the
diagnosis of HLH based on the current combination
of clinical, laboratory and immunological criteria is
challenging because all of the criteria are not specific-
ally diagnostic for any HLH subtypes.
Primary HLH can be further divided into familial
hemophagocytic lymphohistiocytosis (FHL) and immune
deficiencies associated HLH [10]. Five genetic defects
have been identified in FHL. A potential gene locus
(FHL1) has been reported to be associated with HLH,
but the specific gene involved has not yet been identified
[11]. The first described FHL related gene is PRF1 gene
(FHL2) [12], a gene encodes perforin protein. The next
identified cause of FHL (FHL3) is UNC13D gene [13],
which encodes Munc13-4 protein. Later, mutations of
STX11 gene and STXBP2 gene are found to be the
causes of FHL4 [14] and FHL5 [15, 16], respectively. Im-
mune deficiencies associated HLH occur with significant
frequency in X-linked lymphoproliferative syndrome
type 1 (XLP1) [17], XLP type 2 (XLP2) [18], and IL-2–
inducible T cell kinase deficiency-associated lymphopro-
liferation [19], which are characterized by mutations in
SH2D1A, XIAP, and ITK genes, respectively.
Hypercytokinemia is a hallmark of HLH. Henter JI
et al. suggested that hypercytokinemia may be caused by
a genetic defect in cytokine regulation as FHL patients
showed high cytokine levels [20]. Using the rapid cytomet-
ric bead array (CBA) technique, a specific cytokine profile
(significant increase of IFN-γ and IL-10, combined with a
slightly increased level of IL-6) for childhood HLH was
described by our group in 2008 [21]. In our clinical prac-
tice, this cytokine profile was helpful for the early diagno-
sis of HLH and for the differentiation from other disease
entities [22, 23]. However, one limitation of our previous
cytokine assay was that we did not perform genetic
sequencing of HLH involved genes simultaneously. In this
study, we tried to sequence PRF1, UNC13D, STX11,
STXBP2, SH2D1A, XIAP, and ITK genes, together with
cytokine determination for HLH patients to test whether
cytokine profile could be used as a tool to distinguish be-
tween primary HLH and secondary HLH patients.
Methods
Patients
The diagnoses of all our patients were made based on the
HLH-2004 criteria [2]. A cohort of 45 consecutively hospi-
talized HLH patients were enrolled in the study, which in-
cluded 27 males and 18 females with a male-to-female ratio
of 1.5:1, and a mean age of 3.7 years with a range of 8 days
through 12.3 years. Patients who had been treated by ste-
roids before referral to our hospital were excluded. A total
of 50 unrelated healthy individuals (30 males, and 20 fe-
males) matched for age, and race were recruited as healthy
controls. All the patients and healthy controls were from
our hospital between February 2010 and September 2012.
No HLH patient showed signs of mucocutaneous albinism.
The study protocol was reviewed and approved by the Eth-
ics Committee at Children’s Hospital Zhejiang University
School of Medicine and written informed consents were
obtained from all participants’ parents or guardians before
this study.
Genetic analysis
Genomic DNA was isolated from peripheral blood using
QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany). The coding regions and flanking intronic
sequences of PRF1, UNC13D, STX11, STXBP2, SH2D1A,
XIAP, and ITK genes, and the deep intronic sequences of
intron 1 in UNC13D gene were amplified by a polymer-
ase chain reaction (PCR) machine (BIO-RAD) in our la-
boratory, and the PCR products were sequenced by a
DNA sequencer in Invitrogen Company (Shanghai,
China). We analyzed PRF1, UNC13D, STX11, STXBP2,
and ITK genes in all 45 patients and 50 controls, and all
the male patients (n = 27) and male controls (n = 30)
were sequenced in their SH2D1A and XIAP genes. The
mutations were validated by re-sequencing an independ-
ent PCR-generated amplicon from the subjects. The var-
iants were named according to the Human Genome
Variation Society and journal requirements.
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Database investigation and in silico prediction of muta-
tions were checked, including the frequency of each vari-
ant in the general population investigated by Exome
Aggregation Consortium (ExAC, Cambridge, MA, URL:
http://exac.broadinstitute.org, March, 2016 accessed), pre-
vious reports of the same variants in the literature
checked from Human Gene Mutation Database (HGMD,
http://www.hgmd.cf.ac.uk) and Google Scholar (GS,
https://scholar.google.com/), in silico prediction results by
Polymorphism Phenotyping-2 (PolyPhen-2, http://genet-
ics.bwh.harvard.edu/pph2/) and Sorting Intolerant From
Tolerant (SIFT, http://sift.jcvi.org/). For PolyPhen-2,
higher scores mean more deleterious. For SIFT, amino
acids with probabilities < 0.05 were predicted to be
deleterious.
Cytokine determination
All 45 HLH patients and 50 controls were tested for the
six cytokines including IL-2, IL-4, IL-6, IL-10, TNF-α,
and IFN-γ. Peripheral blood samples were collected,
transferred to a serum separating tube and centrifuged
at 1000 g at 20 °C for 20 min after clotting. The serum
was carefully harvested, and the determination of the cy-
tokines was performed immediately, or if the situation
was not so urgent, the aliquot was temporarily stored at
2 °C to 8 °C until analysis (usually within 12 h). Concen-
trations of the six cytokines aforementioned were quan-
titatively determined using the CBA Human Th1/Th2
Cytokine Kit II (BD Biosciences, San Jose, California) as
described previously [21]. The minimum and maximum
limits of detection for all six cytokines were 1 and
5000 pg/ml, respectively.
Degranulation assays with flow cytometry
Degranulation assay were tested in 36 HLH patients and
43 controls. The assay was performed as previously de-
scribed with modifications [24]. Peripheral blood mono-
nuclear cells (PBMC) were isolated by Ficoll gradient
centrifugation, rested in Iscove’s modified Dulbecco
medium (IMDM, Invitrogen, Carlsbad, California, USA)
supplemented with 10 % fetal bovine serum (FBS, Sijiqing,
Hangzhou, China) at 37°C in a humidified atmosphere of
5 % CO2 for 2 h, and washed in 1 × PBS (phosphate buffer
saline). K562 cells were obtained from the American Type
Culture Collection (ATCC, Rockefeller, Maryland, USA)
and cultured in RPMI1640 medium (Invitrogen, Carlsbad,
California, USA) supplemented with 10 % FBS. All the
antibodies including CD3-FITC, CD8-PerCP, CD56-APC,
CD107a-PE (H4A3, IgG1), and isotype controls were pur-
chased from Becton Dickinson (San Jose, CA, USA).
5 × 105 PBMCs were mixed with 5 × 104 sensitive tar-
get cells (K562) as stimulants in 12 flat bottom well
plates and incubated for 2 h at 37°C. An equal volume
of RPMI-1640 culture medium to replace the volume of
K562 cells were used as negative control. Then the cells
were stained with 10μl of CD3-FITC, 10μl of CD8-
PerCP, 2.5μl of CD56-APC, and 10μl of CD107a-PE (iso-
type IgG1-PE as negative control) for 30 min at 4 °C in
the dark. After two washes with 1 × PBS of the above
samples, flow cytometric analyses were performed by a
FACSCalibur cytometer (Becton-Dickinson, San Jose,
CA, USA). CD3-CD56+ and CD3+CD8+ T cells were
gated as NK cells and Cytotoxic T cells (CTLs), respec-
tively. Data were acquired with CellQuest software (BD
Bioscience).
Clinical data
Information at diagnosis of age, sex, with fever or not,
hemoglobin levels, platelets numbers, white blood cell
counts, percentage of neutrophils, total neutrophil
counts, percentage of lymphocytes, total lymphocyte
counts, triglyceride levels, fibrinogen levels, LDH levels,
ferritin levels, sIL2R levels, and sIL2R/ferritin ratio were
collected. Quantitative real-time PCR was used to detect
EBV-DNA and CMV-DNA copies in sera.
Statistical analysis
Serum concentrations of individual cytokines, clinical
data were compared between groups using the Mann-
Whitney U test. A chi-square test was used to assess
ratio differences between groups. Receiver operating
characteristic (ROC) curves were derived from the cyto-
kine levels for all HLH patients. In a ROC curve, the
sensitivity and specificity of all six cytokines were cal-
culated for the differentiation between primary and
secondary HLH. All statistical analyses were performed
using SPSS 17.0 software (SPSS Inc, Chicago, Illinois). A




The genetic findings of the 45 HLH patients were shown
in Table 1, Additional file 1: Figure S1, Additional file 2:
Figure S2, Additional file 3: Figure S3, Additional file 4:
Figure S4, Additional file 5: Figure S5, and Additional
file 6: Figure S6. All variants classified as pathogenic
were not detected in the controls, while those classified
as single nucleotide polymorphisms (SNPs) were found
in both HLH patients and healthy controls. One patient
with biallelic heterozygous mutations in PRF1 gene (P2),
and three patients with hemizygous mutation in
SH2D1A gene (P16, P17 and P26) were categorized into
primary HLH group (n = 4). Based on the available gen-
etic data, the other 41 patients were classified into the
secondary HLH group, including nine HLH patients
with single heterozygous mutation (mutations in patients
P6, P10, and P45 were already reported in literature,
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while mutations in patients P1, P3, P4, P5, P7, and P11
were not reported before), three HLH patients with only
SNPs (P8, P9, and P38), and the remaining 29 HLH
patients without any SNPs.
Mutations in PRF1, UNC13D, STX11, STXBP2,
SH2D1A, XIAP, and ITK genes of all the 45 HLH cases
accounted for 2/45 (4.4 %), 6/45 (13.3 %), 0/45 (0.0 %),
2/45 (4.4 %), 3/45 (6.7 %), 0/45 (0 %), and 0/45 (0.0 %),
respectively. For the four primary HLH cases, mutations
in PRF1 and SH2D1A genes accounted for 1/4 (25 %) and
3/4 (75 %), respectively. Three missense heterozygous var-
iants in PRF1 gene were found in one male and one fe-
male (Additional file 1: Figure S1). One heterozygous
c.385T>A (p.Trp129Arg) mutation was found in P1, a 1-
year-5-month male, while compound heterozygous
c.757G>A (p.Glu253Lys) and c.1061A>T (p.Asp354Val) in
PRF1 gene were found in P2, a 6-year-3-month female,
with c.757G>A inherited from her father and c.1061A>T
from her mother. Five missense mutations of UNC13D
gene (Additional file 2: Figure S2), c.478G>A (p.Val160
Met) in P3, c.518C>T (p.Thr173Met) in P4, c.760C>T
(p.Arg254Cys) in P5, c.3259C>T (p.Arg1087Trp) in P7,
and c.118-307G>A in P45, were found in four males and
one female, respectively. Another heterozygous mutation
c.2296C>T (p.Glu766Ter) in exon23 of UNC13D gene of
an 8-day male patient (P6), with the cDNA study revealed
that this mutation had a deleterious effect on splicing,
c.2295_2298delGCAG (p.Glu765Aspfs*27) (Additional file
6: Figure S6), was already reported by our group as a spe-
cial case [25]. Two heterozygous mutations of STXBP2
gene, c.575G>A (p.Arg192His), and c.767T>C (p.Leu256-
Pro), were identified in two patients (Additional file 3:
Figure S3). Three hemizygous mutations of SH2D1A gene,
c.162C>G (p.Tyr54Ter), c.163C>T (p.Arg55Ter), and
c.191G>A (p.Trp64Ter), were identified in three male pa-
tients (Additional file 4: Figure S4). Two male patients (P8
and P9) with c.497C>T (p.Thr166Met, SNP rs181216956)
of STXBP2 gene, and two male patients (P7 and P38) with
c.1268A>C (p.Gln423Pro, SNP rs5956583) of XIAP gene,
were identified in this cohort (Additional file 5: Figure S5).
No mutation was detected from STX11 and ITK genes in
all 45 HLH patients.
Database investigation and in silico prediction of muta-
tions in HLH patients were shown in Table 2. The in silico
prediction results between PolyPhen-2 and Sorting In-
tolerant From Tolerant (SIFT) were consistent with each
other, except p.Arg1087Trp of UNC13D gene (PolyPhen-2
predicted this change was BENIGN with a score of 0.002,
while SIFT indicated that this change would AFFECT
PROTEIN FUNCTION with a score of 0.00).
Cytokine levels
The mean (95 % Confidence Interval, CI) of serum IL-2,
IL-4, IL-6, IL-10, TNF-α, and IFN-γ concentrations for
Table 1 Summary of genetic findings in 45 HLH patients
Case Gender Age Candidate gene Exon/intron Nucleotide change Amino acid change Genotype






P16 M 3Y3M SH2D1A Exon2 c.191G>A p.Trp64Ter hemizygous
P17 M 11M24D SH2D1A Exon2 c.162C>G p.Tyr54Ter hemizygous
P26 M 11M17D SH2D1A Exon2 c.163C>T p.Arg55 Ter hemizygous
P1 M 1Y5M PRF1 Exon2 c.385T>A p.Trp129Arg heterozygous
P3 M 4Y5M UNC13D Exon6 c.478G>A p.Val160 Met heterozygous
P4 M 2Y8M UNC13D Exon6 c.518C>T p.Thr173Met heterozygous
P5 F 1Y7M UNC13D Exon10 c.760C>T p.Arg254Cys heterozygous
P6 M 8D UNC13D Exon23 c.2296C>T p.Glu766Ter heterozygous
P7 M 25D UNC13D Exon32 c.3259C>T p.Arg1087Trp heterozygous
XIAP Exon5 c.1268A>C p.Gln423Proa hemizygous
P8 M 7Y9M STXBP2 Exon7 c.497C>T p.Thr166Meta heterozygous
P9 M 11Y11M STXBP2 Exon7 c.497C>T p.Thr166 Meta heterozygous
P10 F 5Y8M STXBP2 Exon7 c.575G>A p.Arg192His heterozygous
P11 M 1Y1M STXBP2 Exon9 c.767T>C p.Leu256Pro heterozygous
P38 M 1Y1M XIAP Exon5 c.1268A>C p.Gln423Proa hemizygous
P45 M 4Y UNC13D Intron1 c.118-307G>A Unknown heterozygous
Gender, M male, F female
Age, Y year, M month, D day
aSingle nucleotide polymorphism (SNP)
Ter Terminator, which would result in truncated protein
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Table 2 Database investigation and in silico prediction of mutations in 45 HLH patients










a score of 0.962
POSSIBLY DAMAGING with
a score of 0.952
AFFECT PROTEIN FUNCTION with
a score of 0.01
AFFECT PROTEIN FUNCTION with
a score of 0.02
32.28
P16 SH2D1A c.191G>A p.Trp64Ter Not reported [34, 35] Not Available Not Available 33.83
P17 SH2D1A c.162C>G p.Tyr54 Ter Not reported [36] Not Available Not Available 0.72
P26 SH2D1A c.163C>T p.Arg55 Ter Not reported [36, 37] Not Available Not Available No done
P1 PRF1 c.385T>A p.Trp129Arg Not reported No reference PROBABLY DAMAGING with
a score of 1.000
AFFECT PROTEIN FUNCTION with
a score of 0.00
3.24
P3 UNC13D c.478G>A p.Val160 Met Not reported No reference PROBABLY DAMAGING with
a score of 0.999
AFFECT PROTEIN FUNCTION with
a score of 0.05
35.14
P4 UNC13D c.518C>T p.Thr173Met 0.00001670 No reference PROBABLY DAMAGING with
a score of 1.000
AFFECT PROTEIN FUNCTION with
a score of 0.01
0.43
P5 UNC13D c.760C>T p.Arg254Cys 0.0003450 No reference PROBABLY DAMAGING with
a score of 0.987
AFFECT PROTEIN FUNCTION with
a score of 0.02
5.69
P6 UNC13D c.2296C>T p.Glu766 Ter Not reported [25, 38, 39] Not Available Not Available 0.51
P7 UNC13D c.3259C>T p.Arg1087Trp 0.0001438 No reference BENIGN with a score of 0.002 AFFECT PROTEIN FUNCTION with
a score of 0.00
2.64
XIAP c.1268A>C p.Gln423Pro 0.3334 [40–42] BENIGN with a score of 0.002 TOLERATED with a score of 0.30
P8 STXBP2 c.497C>T p.Thr166Met 0.0002454 No reference BENIGN with a score of 0.022 TOLERATED with a score of 0.10 3.51
P9 STXBP2 c.497C>T p.Thr166 Met 0.0002454 No reference BENIGN with a score of 0.022 TOLERATED with a score of 0.10 13.37
P10 STXBP2 c.575G>A p.Arg192His Not reported [15] PROBABLY DAMAGING with
a score of 1.000
AFFECT PROTEIN FUNCTION with
a score of 0.00
13.73
P11 STXBP2 c.767T>C p.Leu256Pro Not reported No reference PROBABLY DAMAGING with
a score of 1.000
AFFECT PROTEIN FUNCTION with
a score of 0.00
4.7
P38 XIAP c.1268A>C p.Gln423Pro 0.3334 [40–42] BENIGN with a score of 0.002 TOLERATED with a score of 0.30 0.07
P45 UNC13D c.118-307G>A Unknown Not reported [29, 39, 43] Not Available Not Available 3.07
ExAC Exome Aggregation Consortitium, HGMD Human Gene Mutation Database, GS Google Scholar
PolyPhen-2 Polymorphism Phenotyping-2, SIFT Sorting Intolerant From Tolerant












healthy controls were 2.4 (2.2–2.7), 3.2 (2.9–3.5), 6.0
(4.0–7.9), 3.4 (3.0–3.9), 2.9 (2.5–3.4), 9.2 (8.3–10.0) pg/
ml, respectively. As compared to control group, the levels
of IL-4 in both primary and secondary HLH groups were
significantly lower (P < 0.05) while those of IL-6, IL-10
and IFN-γ were significantly higher (P < 0.05) (Fig. 1).
However, the levels of IL-2 and TNF-α were not statisti-
cally different among the three groups (all P > 0.05).
When we compared the levels of the cytokines be-
tween the primary and secondary HLH groups, the IL-
4 level in primary-HLH was significantly lower than
that in secondary HLH (P = 0.025), with mean (95 %
CI) in primary and secondary HLH groups showed as
1.1 (0.6–1.6) and 2.3 (1.9–2.7), respectively. Addition-
ally, IFN-γ level in primary HLH had a tendency of sta-
tistically lower than that in secondary HLH (P = 0.051),
with mean (95 % CI) in primary and secondary HLH
groups showed as 106.6 (minus-393.9) pg/ml and 905.7
(530.7–1280.6) pg/ml, respectively. The 95 % CI gap of
IL-4 between primary and secondary HLH groups was
1.6–1.9 pg/ml, while the gap of IFN-γ between the two
groups was 393.9–530.7 pg/ml. The levels of the
remaining four cytokines including IL-2, IL-6, IL-10, and
TNF-α were not significantly different between primary
and secondary HLH groups (P = 0.78, P = 0.102, P = 0.968,
and P = 0.968, respectively).
Fig. 1 Comparisons of serum cytokine concentrations (pg/ml) among control, primary HLH, and secondary HLH. a IL-2; b IL-4; c IL-6; d IL-10; e TNF-α;
f IFN-γ. The center horizontal line of the central box is the median (50th percentile), the bottom and top of the box are the 25th and 75th percentiles.
The whiskers extend from each end of the box to the 5th and 95th percentiles of the values, respectively. Outliers are the data with values beyond the
5th and 95th percentiles
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The area under the ROC curve, referred to as the AUC,
is an appropriate measure for describing the overall accur-
acy of a diagnostic test, and higher AUC value mean better
diagnostic value. AUCs of IL-4, IFN-γ, IL-10, TNF-α, IL-2,
and IL-6 levels were calculated to be 0.841, 0.799, 0.506,
0.494, 0.457, and 0.250, respectively, indicating that levels
of IL-4 and IFN-γ may be used as additional tools for the
quick differential diagnosis between primary and second-
ary HLH (Fig. 2). ROC curves of IL-4 levels showed that
1.6 pg/ml, 1.7 pg/ml, 1.8 pg/ml, and 1.9 pg/ml had sensi-
tivity and specificity as 73.2 and 75.0 %, 70.7 and 100.0 %,
68.3 and 100.0 %, 63.4 and 100 %, respectively. Further-
more, ROC curves of IFN-γ levels showed that 360.6 pg/
ml, 433.9 pg/ml, and 539.7 pg/ml had sensitivity and spe-
cificity as 51.2 and 75.0 %, 51.2 and 100.0 %, 48.8 and
100 %, respectively. Taken the results of IL-4 and IFN-γ
together, we proposed that HLH patients with IL-4 below
1.7 pg/ml and IFN-γ below 433.9 pg/ml had a higher
chance to be primary HLH.
Degranulation and clinical data
Information of surface CD107a level in resting NK cells,
age at diagnosis, sex, with fever or not, hemoglobin levels,
platelet counts, white blood cell counts, percentage of
neutrophils, absolute neutrophil counts, percentage of
lymphocytes, absolute lymphocyte counts, triglyceride
levels, fibrinogen levels, LDH levels, ferritin levels, sIL2R
levels, sIL2R/ferritin ratio, EBV-DNA, and CMV-DNA
copies were shown in Table 3. The results showed that,
except the percentage of neutrophils (P = 0.012) and the
percentage of lymphocytes (P = 0.012), there was no sig-
nificant difference between primary HLH and secondary
HLH groups in any other factors.
The degranulation assay results in healthy controls,
primary HLH cases, and secondary HLH cases were
shown in Fig. 3, with mean (95 % CI) in controls was
20.9 (18.19–23.6) %. We defined resting NK cell
degranulation below 5 % as defective [26]. The results
showed 0/1 (0 %) patient with FHL2, 1/3 (33.3 %)
patient with XLP, and 15/33 (45.5 %) patients with a
diagnosis of secondary HLH had resting NK degranu-
lation below 5 % (Additional file 7: Table S1). There
was a high possibility that patients with defective de-
granulation could carry undetected mutations.
Meanwhile, we re-grouped HLH patients based on their
CD107a levels in resting NK cells: HLH with CD107a<5 %
(n = 16), and HLH with CD107a>5 % (n = 20). Compari-
sons of serum cytokine concentrations (pg/ml) among
Control, HLH with CD107a<5 %, and HLH with
CD107a>5 % were shown in Additional file 8: Figure S7,
indicated similar results to primary and secondary HLH
grouping. Comparing to the healthy control group, both
HLH with CD107a<5 % and CD107a>5 % had higher
IL-6, IL-10 and IFN-γ levels, and lower IL-4 level (with
all P < 0.05). Between HLH with CD107a<5 % and
CD107a>5 % groups, all six cytokines showed no statis-
tical significance.
Discussion
Inheritance of HLH is known to be autosomal recessive.
Based on the data from published studies, primary HLH
usually includes patients with homozygous, hemizygous,
or compound heterozygous mutations, as mutations of
these types affect protein function in a known way. In
our HLH patients, no homozygous mutation was de-
tected, and all were hemizygous or heterozygous vari-
ants. Similar to our results, Zhizhuo H et al. investigated
67 Chinese HLH patients and identified eight patients
with variants in primary HLH related genes, included
one patient with a hemizygous mutation of XIAP gene,
three patients with compound heterozygous mutations,
and four patients with single heterozygous mutation
[27]. How does the single heterozygous mutation affect
its coding protein’s function is complicated and remains
to be elucidated. Based on the recent study of Spessott
WA et al. in 2015 [28], some single heterozygous muta-
tion in special site can cause primary HLH, yet the dom-
inant negative effect can not be generalized, and people
should do further study to prove the related protein
function is damaged if they want to assign some HLH
patients with monoallelic mutation as primary HLH. An-
other possibility is that the risk of having missed patho-
genic variants is high, and possible additional variants,
such as deep intronic variants similar to mutations in
deep intron 1 of UNC13D gene [29–31], might have
been missed for some cases.
In our previous study, we found that HLH patients
presented a specific cytokine profile of highly increased
levels of IFN-γ and IL-10, and a moderately increased
level of IL-6 [23]. In this study, the levels of IL-6, IL-10,
and IFN-γ in both primary and secondary HLH groups
Fig. 2 ROC curves of IL-2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ between
primary HLH and secondary HLH. The diagonal line is the reference line
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were significantly higher (P < 0.05) than those of con-
trols, and no patient was overlapped with our previous
study, which further confirmed the usefulness of this
cytokine profile for the diagnosis of HLH.
When we compared the levels of the cytokines between
the primary and secondary HLH groups, the IL-4 level in
primary-HLH was significantly lower than that in second-
ary HLH (P = 0.025), with the gap of IL-4 between the two
groups was 1.6–1.9 pg/ml, and IFN-γ level in primary
HLH had a tendency of statistically lower than that in sec-
ondary HLH (P = 0.051), with the gap of IFN-γ between
the two groups was 393.9–530.7 pg/ml. AUCs of six cyto-
kines indicated that levels of IL-4 and IFN-γ may be used
as additional tools for the quick differential diagnosis
between primary and secondary HLH. Taken the results
of IL-4 and IFN-γ together, we propose that HLH patients
Table 3 Clinical information on 45 HLH patients
Total (n = 45) Primary (n = 4) Secondary (n = 41) P-value
Age at diagnosis
≤12 months 9/45 2/4 7/41 0.116
>12 months 36/45 2/4 34/41
Mean age (year, range) 3.7 (0–12.3) 2.9 (1.0–6.3) 3.8 (0–12.3) 0.646
Sex (M/F) 27/18 3/1 24/17 0.521
Fever 45/45 4/4 41/41
Hemoglobin (<90 g/L) 16/45 1/4 15/41 0.644
Mean (g/L, range) 94.0 (46.0–135.0) 93.8 (84.0–102.0) 94.0 (46.0–135.0) 0.905
Platelets (<100x109/L) 30/45 2/4 28/41 0.459
Mean (100x109/L, range) 82.5 (32.0–400.0) 100.0 (5.0–215.0) 80.8 (3.0–400.0) 0.661
White blood cells
Mean (1x109/L, range) 7.5 (0.3–41.3) 6.5 (1.0–9.7) 7.6 (0.3–41.3) 0.842
Percentage of neutrophils
Mean (%, range) 38.2 (2.0–81.5) 12.8 (6.9–19.4) 40.7 (2.0–81.5) 0.012
Total neutrophils (<1x109/L) 20/45 2/4 18/41 0.815
Mean (1x109/L, range) 2.9 (0.1–22.1) 0.9 (0.1–1.3) 3.1 (0.1–22.1) 0.413
Percentage of lymphocytes
Mean (%, range) 50.4 (7.9–88) 75.3 (71.8–77.7) 48.0 (7.9–88.0) 0.012
Total lymphocytes
Mean (1x109/L, range) 3.6 (0.2–28.1) 4.9 (0.7–7.5) 3.4 (0.2–28.1) 0.175
Triglycerides (>3.0 mmol/L) 15/45 3/4 12/41 0.064
Mean (mmol/L, range) 2.7 (0.8–8.9) 3.0 (1.3–4.1) 2.7 (0.8–8.9) 0.425
Fibrinogen (<1.5 g/L) 30/45 4/4 26/41 0.138
Mean (g/L, range) 1.5 (0.2–4.9) 0.9 (0.5–1.2) 1.5 (0.2–4.9) 0.14
LDH (>500 IU/L) 32/45 3/4 29/41 0.857
Mean (IU/L, range) 1018.0 (167.0–6565.0) 814.0 (363.0–1644.0) 1037.9 (167.0–6565.0) 0.842
Ferritin (>500 μg/L) 45/45 4/4 41/41
Mean (μg/L, range) 1477.7 (895.0–1500.0) 1500.0 (1500.0–1500.0) 1474.2 (895.0–1500.0) 0.655
sIL2R (≥2400 U/ml) 26/27 4/4 22/23 0.671
Mean (U/ml, range) 34092.7 (155.6–85787.7) 27198.1 (14250.9–38203.1) 35239.6 (155.6–85787.7) 0.922
sIL2R/Ferritin
Mean (U/pg, range) 23.0 (0.1–57.2) 18.4 (9.5–25.5) 23.8 (0.1–57.2) 0.811
Degranulation (CD107a <5 %) 16/36 1/3 15/33 0.795
Mean (%, range) 10.3 (0.1–35.1) 22.3 (0.7–33.8) 9.2 (0.1–35.1) 0.407
EBV-DNA (>1000 copies) 26/45 2/4 24/41 0.741
CMV-DNA (>1000 copies) 1/45 0/4 1/41 0.752
P value: Comparisons between primary and secondary HLH groups
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with IL-4 below 1.7 pg/ml and IFN-γ below 433.9 pg/ml
have a higher possibility to be primary HLH.
There have been studies trying to find other discrimi-
nators to differentiate primary from secondary cases of
HLH. According to the report by Bryceson et al. [26],
degranulation assay has a high sensitivity and specificity
rate for discrimination between two types of HLH (type1
includes FHL3, FHL4, and FHL5, while type2 includes
FHL2, XLP1, XLP2, and secondary HLH cases). In this
cohort, all primary HLH cases belong to type2 HLH in-
cluding FHL2 and XLP1, and it is not surprising that we
can not find difference of degranulation between pri-
mary HLH and secondary HLH groups. Yasumi et al.
proposed that the percentage of total lymphocytes,
serum levels of LDH, and the sIL2R/ferritin ratio could
differentiate familial from secondary HLH [32]. In this
study, when we compare to the secondary HLH patients,
primary HLH patients have higher percentage of
lymphocytes (mean level 75.3 % vs 48.0 %, P = 0.012),
and lower percentage of neutrophils (12.8 % vs 40.7 %,
P = 0.012), which is consistent with Yasumi et al’s findings.
Our study has some limitations. First, the risk of having
missed pathogenic variants is high, and possible additional
variants, such as deep intronic variants, regulatory vari-
ants, and complex structural variants, might have been
missed for some cases, which would have great impact on
the grouping strategy and then influence the interpretation
of the results. Second, as this is a single-center study,
and the results are based on data from small number of
samples and incomplete genetic sequencing results, a
multi-center study was required to be performed to vali-
date the results.
Conclusions
Among 45 HLH patients, four HLH patients are identified
as primary HLH with hemizygous or compound heterozy-
gous mutations, and 41 HLH patients belong to secondary
HLH. Variants in PRF1, UNC13D, STX11, STXBP2,
SH2D1A, XIAP, and ITK genes account for 2/45 (4.4 %), 6/
45 (13.3 %), 0/45 (0.0 %), 2/45 (4.4 %), 3/45 (6.7 %), 0/45
(0 %), and 0/45 (0.0 %), respectively. HLH patients with
lower IL-4 level, lower IFN-γ level, higher percentage of
lymphocytes, and lower percentage of neutrophils have
higher possibility to be primary HLH. The cytokine profiles
can be used as an additional tool for the quick differential
diagnosis between primary and secondary HLH.
Additional files
Additional file 1: Figure S1. Sequencing results of PRF1 gene.
Genomic DNA sequencing results showed a 1-year-5-month male (P1)
had heterozygous mutation c.385T>A (p.Trp129Arg), and a 6-year-3-month
female (P2) had compound heterozygous c.757G>A (p.Glu253Lys) and
c.1061A>T (p.Asp354Val) of PRF1 gene. (TIF 1391 kb)
Fig. 3 Degranulation results of healthy controls, primary HLH cases, and pecondary HLH cases. Shapes represent individual subjects, while horizontal
bars show the mean in each group
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Additional file 2: Figure S2. Sequencing results of UNC13D gene.
Five missense mutations of UNC13D gene, c.478G>A (p.Val160 Met)
in P3, c.518C>T (p.Thr173Met) in P4, c.760C>T (p.Arg254Cys) in P5,
c.3259C>T(p.Arg1087Trp) in P7, and c.118-307G>A in P45, were found
in four males and one female, respectively. (TIF 171 kb)
Additional file 3: Figure S3. Sequencing results of STXBP2 gene. Two
mutations of STXBP2 gene, c.575G>A (p.Arg192His) in P10, and c.767T>C
(p.Leu256Pro) in P11, were found in one male and one female,
respectively. (TIF 985 kb)
Additional file 4: Figure S4. Sequencing results of SH2D1A gene. Three
hemizygous mutations of SH2D1A gene, c.191G> (p.Trp64Ter) in P16,
c.162C>G(p.Tyr54Ter) in P17, and c.163C>T(p.Arg55Ter) in P26, were
identified in three male patients, respectively. (TIF 136 kb)
Additional file 5: Figure S5. SNPs of STXBP2 and XIAP genes. Two
males patients, 7-year-9-month (P8) and 11-year-11-month (P9), showed
c.497C>T (p.Thr166Met) in STXBP2 gene, numbered SNP rs181216956; of
XIAP gene, two male patients (P7 and P38) were identified with
c.1268A>C(p.Gln423Pro), numbered SNP rs5956583. (TIF 938 kb)
Additional file 6: Figure S6. Sequencing results of UNC13D gene in a
Chinese male neonate(P6) and his parents. In mRNA level of P6, the result
manifested a heterozygous frameshift mutation c.2295_2298delGCAG (A),
which was consistent with the heterozygous point mutation c.2296C>T in
genomic DNA level (B). Sequencing results from cDNA and genomic DNA
of P6 and his parents both showed that P6 inherited this mutation from
his mother. (TIF 391 kb)
Additional file 7: Table S1. Percentage of CD107a expression in NK
cells from 43 controls and 36 HLH patients. (DOCX 15 kb)
Additional file 8: Figure S7. Comparisons of serum cytokine
concentrations (pg/ml) among control, HLH with CD107a<5 %, and HLH
with CD107a>5 %. A: IL-2; B: IL-4; C: IL-6; D: IL-10; E: TNF-α; F: IFN-γ. The
center horizontal line of the central box is the median (50th percentile), the
bottom and top of the box are the 25th and 75th percentiles. The whiskers
extend from each end of the box to the 5th and 95th percentiles of the
values, respectively. Outliers are the data with values beyond the 5th and
95th percentiles. (TIF 957 kb)
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